Loading...
Header Logo
Keywords
Last Name
Institution

XUELIN HUANG

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Badar T, Shetty A, Bueso-Ramos C, Cortes J, Konopleva M, Borthakur G, Pierce S, Huang X, Chen HC, Kadia T, Daver N, Dinardo C, O'Brien S, Garcia-Manero G, Kantarjian H, Ravandi F. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73. PMID: 26017166.
      View in: PubMed
    2. Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015 Feb 15; 121(4):556-61. PMID: 25336333.
      View in: PubMed
    3. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468.
      View in: PubMed
    4. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014 Sep; 15(10):1090-9. PMID: 25150798.
      View in: PubMed
    5. Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52. PMID: 24952901.
      View in: PubMed
    6. Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML. Apoptosis. 2014 Apr; 19(4):698-707. PMID: 24337870.
      View in: PubMed
    7. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014 Apr 15; 20(8):2226-35. PMID: 24583795.
      View in: PubMed
    8. Huang X, Ning J, Wahed AS. Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med. 2014 Jun 30; 33(14):2363-78. PMID: 24510534.
      View in: PubMed
    9. Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):327-334.e8. PMID: 24594142.
      View in: PubMed
    10. Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7. PMID: 24447728.
      View in: PubMed
    11. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, Elashoff M, Konopleva M, Cardone MH, Andreeff M. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013 Dec; 12(12):2940-9. PMID: 24092807.
      View in: PubMed
    12. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients =60 years with newly diagnosed acute myeloid leukemia. Am J Hematol. 2013 Nov; 88(11):961-6. PMID: 23877926.
      View in: PubMed
    13. Rao X, Lai D, Huang X. A new method for quantitative real-time polymerase chain reaction data analysis. J Comput Biol. 2013 Sep; 20(9):703-11. PMID: 23841653.
      View in: PubMed
    14. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21. PMID: 23836561.
      View in: PubMed
    15. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693.
      View in: PubMed
    16. Choi S, Huang X. A general class of semiparametric transformation frailty models for nonproportional hazards survival data. Biometrics. 2012 Dec; 68(4):1126-35. PMID: 23005582.
      View in: PubMed
    17. Luo S, Yi M, Huang X, Hunt KK. A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. Stat Med. 2013 Jun 15; 32(13):2320-34. PMID: 22996169.
      View in: PubMed
    18. Cai G, Li H, Lu Y, Huang X, Lee J, Müller P, Ji Y, Liang S. Accuracy of RNA-Seq and its dependence on sequencing depth. BMC Bioinformatics. 2012; 13 Suppl 13:S5. PMID: 23320920.
      View in: PubMed
    19. Huang X, Ning J. Analysis of multi-stage treatments for recurrent diseases. Stat Med. 2012 Oct 30; 31(24):2805-21. PMID: 22826139.
      View in: PubMed
    20. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood. 2012 Jul 05; 120(1):173-80. PMID: 22645176.
      View in: PubMed
    21. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51. PMID: 22534616.
      View in: PubMed
    22. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012 May; 157(3):312-20. PMID: 22360602.
      View in: PubMed
    23. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012 Jun 15; 118(12):3123-7. PMID: 22294282.
      View in: PubMed
    24. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. 2012 Sep 15; 118(18):4471-7. PMID: 22282348.
      View in: PubMed
    25. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7. PMID: 22228624.
      View in: PubMed
    26. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1a-mediated down-regulation of CXCL12. Blood. 2011 Oct 20; 118(16):4431-9. PMID: 21868571.
      View in: PubMed
    27. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011 Jun 20; 29(18):2507-13. PMID: 21555694.
      View in: PubMed
    28. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011 May 20; 30(11):1218-29. PMID: 21432894.
      View in: PubMed
    29. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 03; 117(5):1662-9. PMID: 21115978.
      View in: PubMed
    30. Ning J, Huang X. Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Stat Med. 2010 Jul 30; 29(17):1761-8. PMID: 20658546.
      View in: PubMed
    31. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol. 2010 Apr 01; 28(10):1766-71. PMID: 20159819.
      View in: PubMed
    32. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma. 2010 Jan; 51(1):73-8. PMID: 20017599.
      View in: PubMed
    33. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 01; 28(4):605-13. PMID: 20038729.
      View in: PubMed
    34. Sharabi AB, Lee SH, Goodell MA, Huang XF, Chen SY. Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells. 2009 Dec; 11(4):523-33. PMID: 20025523.
      View in: PubMed
    35. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer. 2009 Oct 15; 115(20):4737-44. PMID: 19637342.
      View in: PubMed
    36. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30. PMID: 19805674.
      View in: PubMed
    37. Hong B, Ren W, Song XT, Evel-Kabler K, Chen SY, Huang XF. Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res. 2009 Oct 15; 69(20):8076-84. PMID: 19789342.
      View in: PubMed
    38. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec; 23(12):2275-80. PMID: 19741728.
      View in: PubMed
    39. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009 Sep; 17(9):1626-36. PMID: 19532135.
      View in: PubMed
    40. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med. 2009 May 30; 28(12):1680-9. PMID: 19326367.
      View in: PubMed
    41. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009 Jul; 23(7):1297-302. PMID: 19242494.
      View in: PubMed
    42. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56. PMID: 19238013.
      View in: PubMed
    43. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6. PMID: 18756533.
      View in: PubMed
    44. Liu L, Huang X. The use of Gaussian quadrature for estimation in frailty proportional hazards models. Stat Med. 2008 Jun 30; 27(14):2665-83. PMID: 17910008.
      View in: PubMed
    45. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45. PMID: 18565853.
      View in: PubMed
    46. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7. PMID: 18320602.
      View in: PubMed
    47. Song XT, Evel-Kabler K, Shen L, Rollins L, Huang XF, Chen SY. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med. 2008 Mar; 14(3):258-65. PMID: 18311150.
      View in: PubMed
    48. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45. PMID: 18085610.
      View in: PubMed
    49. Huang X, Zhang N. Regression survival analysis with an assumed copula for dependent censoring: a sensitivity analysis approach. Biometrics. 2008 Dec; 64(4):1090-9. PMID: 18266895.
      View in: PubMed
    50. Cook RJ, Zeng L, Lee KA. A multistate model for bivariate interval-censored failure time data. Biometrics. 2008 Dec; 64(4):1100-9. PMID: 18218064.
      View in: PubMed
    51. Liu L, Huang X, O'Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics. 2008 Sep; 64(3):950-8. PMID: 18162110.
      View in: PubMed
    52. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008 Mar; 22(3):538-43. PMID: 18079733.
      View in: PubMed
    53. Aldrich M, Sanders D, Lapteva N, Huang XF, Chen SY. SOCS1 downregulation in dendritic cells promotes memory T-cell responses. Vaccine. 2008 Feb 20; 26(8):1128-35. PMID: 18222020.
      View in: PubMed
    54. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15; 111(4):1816-9. PMID: 18039954.
      View in: PubMed
    55. Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. Br J Haematol. 2007 Aug; 138(4):555-7. PMID: 17593249.
      View in: PubMed
    56. Huang X, Liu L. A joint frailty model for survival and gap times between recurrent events. Biometrics. 2007 Jun; 63(2):389-97. PMID: 17688491.
      View in: PubMed
    57. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A parallel phase I/II clinical trial design for combination therapies. Biometrics. 2007 Jun; 63(2):429-36. PMID: 17688495.
      View in: PubMed
    58. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007 Mar 15; 109(6):1133-7. PMID: 17315156.
      View in: PubMed
    59. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007 Mar 15; 109(6):1152-6. PMID: 17315232.
      View in: PubMed
    60. Huang X, Cormier JN, Pisters PW. Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases. Biometrics. 2006 Sep; 62(3):901-9. PMID: 16984334.
      View in: PubMed
    61. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7. PMID: 16882708.
      View in: PubMed
    62. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20. PMID: 16568458.
      View in: PubMed
    63. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62. PMID: 16497968.
      View in: PubMed
    64. Song XT, Evel-Kabler K, Rollins L, Aldrich M, Gao F, Huang XF, Chen SY. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med. 2006 Jan; 3(1):e11. PMID: 16381597.
      View in: PubMed
    65. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark. 2006; 2(3-4):97-101. PMID: 17192064.
      View in: PubMed
    66. Evel-Kabler K, Song XT, Aldrich M, Huang XF, Chen SY. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest. 2006 Jan; 116(1):90-100. PMID: 16357940.
      View in: PubMed
    67. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics. 2005 Dec; 61(4):992-9. PMID: 16401272.
      View in: PubMed
    68. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT. Clin Radiol. 2005 Jun; 60(6):700-9. PMID: 16038698.
      View in: PubMed
    69. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004 Nov 15; 22(22):4567-74. PMID: 15542808.
      View in: PubMed
    70. Ren W, Strube R, Zhang X, Chen SY, Huang XF. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res. 2004 Sep 15; 64(18):6645-51. PMID: 15374979.
      View in: PubMed
    71. Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics. 2004 Sep; 60(3):747-56. PMID: 15339298.
      View in: PubMed
    72. Huang X, Wolfe RA, Hu C. A test for informative censoring in clustered survival data. Stat Med. 2004 Jul 15; 23(13):2089-107. PMID: 15211605.
      View in: PubMed
    73. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol. 2004 Jul; 17(7):790-7. PMID: 15073602.
      View in: PubMed
    74. Shen L, Schroers R, Hammer J, Huang XF, Chen SY. Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother. 2004 May; 53(5):391-403. PMID: 14624313.
      View in: PubMed
    75. Huang XF, Ren W, Rollins L, Pittman P, Shah M, Shen L, Gu Q, Strube R, Hu F, Chen SY. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. 2003 Nov 01; 63(21):7321-9. PMID: 14612530.
      View in: PubMed
    76. Chang KC, Huang X, Medeiros LJ, Jones D. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003 Nov; 201(3):404-12. PMID: 14595752.
      View in: PubMed
    77. Van Harrison R, Janz NK, Wolfe RA, Tedeschi PJ, Stross JK, Huang X, McMahon LF. Characteristics of primary care physicians and their practices associated with mammography rates for older women. Cancer. 2003 Nov 01; 98(9):1811-21. PMID: 14584062.
      View in: PubMed
    78. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderstrup G, Huang XF, Chen SY. Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res. 2003 Oct 15; 9(13):4743-55. PMID: 14581345.
      View in: PubMed
    79. Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res. 2003 Aug 15; 9(9):3260-71. PMID: 12960111.
      View in: PubMed
    80. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Huang X, McMahon LF. 5-Year mammography rates and associated factors for older women. Cancer. 2003 Mar 01; 97(5):1147-55. PMID: 12599219.
      View in: PubMed
    81. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Chernew M, Stross JK, Huang X, McMahon LF. Personalized targeted mailing increases mammography among long-term noncompliant medicare beneficiaries: a randomized trial. Med Care. 2003 Mar; 41(3):375-85. PMID: 12618641.
      View in: PubMed
    82. Huang X, Wolfe RA. A frailty model for informative censoring. Biometrics. 2002 Sep; 58(3):510-20. PMID: 12229985.
      View in: PubMed
    83. Schroers R, Huang XF, Hammer J, Zhang J, Chen SY. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res. 2002 May 01; 62(9):2600-5. PMID: 11980655.
      View in: PubMed
    84. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment. 154:495-508.
    85. Maximum likelihood estimation of semiparametric mixture component models for competing risks data. Biometrics. 70:588-598.
    86. Efficient semiparametric mixture inferences on cure rate models for competing risks. Canadian Journal of Statistics. 43:420-435.
    87. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. 8.
    88. Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs. PLoS One. 10.
    89. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia.
    90. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology.
    91. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    92. A semiparametric inverse-Gaussian model and inference for survival data with a cured proportion. Canadian Journal of Statistics. 42:635-649.
    93. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia. The Lancet Haematology.
    94. Adaptive and sequential methods for clinical trials. Journal of Probability and Statistics.
    95. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia.
    96. A Bayesian multivariate joint frailty model for disease recurrences and survival. Statistics in Medicine. 35:4794-4812.
    97. On the dependence structure of bivariate recurrent event processes. Biometrika. 102:345-358.
    98. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Science Signaling. 9.
    99. Joint frailty models for zero-inflated recurrent events in the presence of a terminal event. Biometrics. 72:204-214.
    100. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.
    101. Quantile residual life regression with longitudinal biomarker measurements for dynamic prediction. Journal of the Royal Statistical Society. Series C: Applied Statistics.
    102. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. The Lancet Oncology. 16:1547-1555.
    103. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Statistics in Medicine. 34:3424-3443.
    104. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. American Journal of Hematology.
    105. A two-stage approach for dynamic prediction of time-to-event distributions. Statistics in Medicine.
    106. Results of the phase i trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clinical Cancer Research. 22:868-876.
    107. Comparison of Analytic Methods for Quantitative Real-Time Polymerase Chain Reaction Data. Journal of Computational Biology. 22:988-996.
    108. Decitabine response with chromosome 7 abnormality in MDS, and decitabine optimal schedule [10]. Blood. 110:1083.
    109. Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome. Journal of the Royal Statistical Society. Series C: Applied Statistics. 58:65-81.
    110. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    111. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 30:268-273.
    112. Modified SuperCurve Method for Analysis of Reverse-Phase Protein Array Data. Journal of Computational Biology. 22:765-769.
    HUANG's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description